Active — Not RecruitingNot Applicable

Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes

South Korea76 participantsStarted 2022-08-29

Plain-language summary

This study is to investigate the therapeutic effect and treatment results of radiofrequency ablation using the Octopus MP electrode capable of temperature monitoring and drug injection and a variable-length electrode for treatment of small hepatocellular carcinomas (≤ 3cm).

Who can participate

Age range20 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Child-Pugh Class A or B * chronic hepatitis B or chronic hepatitis C or liver cirrhosis * presence of hepatocellular carcinoma (HCC) after confirmed by pathology or imaging studies including contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) according to the Korean Liver Cancer Study Group (KLCSG)-National Cancer Center (NCC) Korea practice guidelines. * up to 3 lesions, each greater than less than or equal to 3 cm at the time of locoregional treatment. Exclusion Criteria: * number of recurrent HCCs, more than 3 * largest HCC size over 3 cm * presence of vascular invasion by HCC * platelet count less than 40,000 per mm3 or International Normalized Ratio (INR) prolongation over 50% * presence of extrahepatic metastasis

What they're measuring

Local tumor progression rates

Timeframe: 1 and 2 years after radiofrequency ablation

Adjacent organ thermal injury rate

Timeframe: Immediately after radiofrequency ablation

Trial details

NCT IDNCT05666271

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08-30

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials